GRAIL's Galleri multi-cancer blood test won an FDA advisory panel recommendation for approval on September 23, 2026 — despite missing its primary surrogate endpoint in a 140,000-person randomized trial. The panel vote places the test on a path to taxpayer-funded Medicare reimbursement under legislation enacted earlier in 2026.

What did the trial actually measure?

GRAIL enrolled 140,000 participants in a randomized study comparing Galleri against standard cancer screening. The company selected a surrogate endpoint rather than a direct measure of cancer mortality, a design choice critics label suboptimal. The trial then failed to meet even the surrogate. An opinion essay published October 6 in STAT News frames the situation bluntly: "There must be some mistake" in recommending approval for a test that did not reach its pre-specified target on a softened metric.

Why does the surrogate matter?

Surrogate endpoints substitute for harder outcomes: late-stage incidence or mortality in oncology. They compress trial timelines and cut costs, but they carry model risk. A therapeutic — or a screening tool — can move the surrogate without moving survival. For a multi-cancer screening test, the clinical question is straightforward: does early detection change death rates from the cancers the assay claims to find? A surrogate that misses its target gives no quantitative answer.

GRAIL's regulatory file therefore rests on a metric it could not positively demonstrate. Laboratory directors, hospital procurement officers and health economics teams must now assess a product without a positive efficacy readout at registration. That is a different evidence posture than typical 510(k) or PMA clearances, where pre-specified endpoints usually hold.

What does the Medicare coverage act change?

The Medicare Multi-Cancer Early Detection Screening Coverage Act, passed earlier in 2026, opens a reimbursement pathway for CMS once FDA clears a qualifying multi-cancer test. If Galleri clears the agency, taxpayer dollars fund a screen that has not validated its own primary endpoint. Coverage statutes typically anchor payment to demonstrated benefit; layering reimbursement on top of an FDA decision built on a missed surrogate reverses that chain.

For R&D managers, the sequence matters. A panel vote that diverges from pre-specified endpoints does not just reset one product. It shifts the negotiating stance of every hospital system, insurer and CMS contractor evaluating next-generation liquid-biopsy programs in 2027 and beyond.

How should diagnostics teams read this?

Two operational signals emerge for research managers running their own pipelines:

• Endpoint choice outlives the trial. Picking a surrogate to shorten timelines locks a sponsor into that metric's success criteria at FDA and in litigation for years after launch.
• Payer logic now stacks on FDA logic. A panel green light no longer binds — statutory coverage can amplify, or override, the underlying scientific judgment.

Investigators, IRBs and biostatistics groups should treat panel votes that diverge from pre-specified endpoints as a prompt to revisit pivotal-study design before committing capital and patient enrollment.

What comes next?

The FDA typically follows advisory panel recommendations, though it can deviate. A final agency decision will determine whether Medicare reimbursement flows automatically under the 2026 act, or whether the regulator seeks additional efficacy data before clearing Galleri. Disclosure of the full trial results and the FDA's own briefing documents stands as the most likely near-term catalyst, with the original STAT News commentary continuing to draw scrutiny to the data package GRAIL submitted.